Stocklytics Platform
Asset logo for symbol ZNTL
Zentalis Pharmaceuticals
ZNTL37
$1.51arrow_drop_up0.99%$0.01
Penny Stock
Asset logo for symbol ZNTL
ZNTL37

$1.51

arrow_drop_up0.99%
Key Stats
Open$1.49
Prev. Close$1.50
EPS-2.50
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$92.63M
PE Ratio-
LOWHIGH
Day Range1.45
1.54
52 Week Range1.05
21.34
Ratios
Revenue-
EBITDA Margin %-
EPS-2.50
Fundamentals
Gross Profit-
Payout Ratio-
Industry average yield2.87%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell

Analyst rating

An aggregate view of professional's ratings.

—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell

Stock Performance

ZNTL-
US Healthcare Sector-
US Market-
warning

ZNTL / Market

ZNTL lose to the US Market which returned 1.29% over the last twenty four hours.
warning

ZNTL / Healthcare Sector

ZNTL lose to the US Healthcare sector which returned 3.64% over the last twenty four hours.

Zentalis Pharmaceuticals (ZNTL) Statistics

Zentalis Pharmaceuticals Inc (ZNTL) is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics targeting oncology indications. The company's mission is to deliver innovative treatments to cancer patients in need. With its strong pipeline and proprietary platform, Zentalis Pharmaceuticals is well-positioned to address the unmet medical needs in oncology.
In terms of valuation metrics, ZNTL stock has been performing well. The stock has a high enterprise value to EBITDA ratio, indicating strong financial performance. Additionally, the company has a healthy profit margin, demonstrating its ability to generate profits from its operations. Zentalis Pharmaceuticals also has a low level of total debt, which is positive for investors.
ZNTL stock's performance has been favorable compared to the sector. The company has consistently outperformed its peers, reflecting the strength of its business model and the potential of its pipeline. This is further supported by ZNTL's revenue per share, which has been increasing over time.
The CEO of Zentalis Pharmaceuticals Inc, ZNTL is Dr. Anthony Sun. Dr. Sun has extensive experience in the biopharmaceutical industry and has played a crucial role in the success of the company. Under his leadership, Zentalis Pharmaceuticals has achieved significant milestones and continues to make progress in its mission to provide effective treatments for cancer patients.
The gross profit of Zentalis Pharmaceuticals Inc, ZNTL has been impressive. The company has successfully generated substantial revenue from its operations, resulting in a strong gross profit. This indicates the company's ability to effectively manage its costs and generate value for its shareholders.
In summary, Zentalis Pharmaceuticals Inc (ZNTL) is a biopharmaceutical company with a focus on oncology therapeutics. The company has solid fundamentals, including strong valuation metrics, favorable stock performance compared to the sector, and a successful CEO leading the business. With its innovative pipeline and commitment to cancer patients, Zentalis Pharmaceuticals is positioned for continued success in the biopharmaceutical industry.
add Zentalis Pharmaceuticals to watchlist

Keep an eye on Zentalis Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Zentalis Pharmaceuticals (ZNTL) stock's performance compared to its sector and the market over the past year?

Over the past year, Zentalis Pharmaceuticals (ZNTL) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 23.41%, Zentalis Pharmaceuticals has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 35.60%, it has fallen short of the market average. This comparison highlights Zentalis Pharmaceuticals 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Zentalis Pharmaceuticals (ZNTL) stock?

The PE ratio for Zentalis Pharmaceuticals (ZNTL) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Zentalis Pharmaceuticals (ZNTL) stock?

The Earnings Per Share (EPS) for Zentalis Pharmaceuticals (ZNTL), calculated on a diluted basis, is -$2.5. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Zentalis Pharmaceuticals (ZNTL) stock?

The operating margin for Zentalis Pharmaceuticals (ZNTL) is -515.94%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Zentalis Pharmaceuticals (ZNTL) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Zentalis Pharmaceuticals (ZNTL) is -$207.96M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Zentalis Pharmaceuticals (ZNTL) have?

Zentalis Pharmaceuticals (ZNTL) has a total debt of $43.27M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$863K.

Take Your Investments to a Whole New Level